IP Verse

Therapeutic Uses Of Empagliflozin - EP2981255B1

PatentPatent Analysis

EP2981255

BOEHRINGER INGELHEIM
Application Number
EP14715274A
Filing Date
Apr 3, 2014
Status
Granted And Under Opposition
Aug 12, 2022
Grant Date
Sep 14, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2488145B1
EP3150200B1
EP2395968B1

Bibliography

The patent EP2981255B1 was granted to Boehringer Ingelheim on Sep 14, 2022 following the initial filing on Apr 3, 2014 under the application number EP14715274A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJun 14, 2023ADMISSIBLE
HGFJun 14, 2023ADMISSIBLE
ADALVOJun 13, 2023ADMISSIBLE
AERAJun 13, 2023ADMISSIBLE
SANOVEL IIAC SAN VE TICJun 13, 2023ADMISSIBLE
STADA ARZNEIMITTELJun 13, 2023ADMISSIBLE
ZENTIVA KSJun 13, 2023ADMISSIBLE
POLPHARMAJun 8, 2023ADMISSIBLE
SANDOZJun 8, 2023ADMISSIBLE
TEVA PHARMACEUTICALSApr 20, 2023ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents